Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-07

Study Completion Date

2024-11-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to evaluate the tolerability of the new formulation of Dorzolamide+Timolol preservative free developed in OSD Aptar Pharma multidose system in comparison with Dorzolamide +Timolol BAK preserved ophthalmic formulation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

NCT00449956

Glaucoma

COMPLETED PHASE3

24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination

NCT00972257

Glaucoma

COMPLETED PHASE4

Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure

NCT00906594

Glaucoma

COMPLETED PHASE4

Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide

NCT01062971

Primary Open Angle Glaucoma Ocular Hypertension

COMPLETED PHASE2

Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT00822081

Open-Angle Glaucoma Ocular Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma, Open-Angle Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dorzolamide+Timolol PF

Glaucotensil TD LC, Laboratorios Poen

Group Type EXPERIMENTAL

Dorzolamide / Timolol Ophthalmic Solution

Intervention Type DRUG

Dorzolamide-timolol fixed combination in a preservative-free multidose device

Dorzolamide + Timolol BAK

Glaucotensil TD, Laboratorios Poen

Group Type EXPERIMENTAL

dorzolamide/timolol

Intervention Type DRUG

Dorzolamide-timolol BAK-preserved fixed combination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dorzolamide / Timolol Ophthalmic Solution

Dorzolamide-timolol fixed combination in a preservative-free multidose device

Intervention Type DRUG

dorzolamide/timolol

Dorzolamide-timolol BAK-preserved fixed combination

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glaucotensil TD LC Glaucotensil TD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Older than 18 years old
* Patients with POAG and OH
* PIO \< 20 mmHg
* Under treatment with Dorzolamide + Timolol BAK preserved at least 6 month after
* OSDI \> 13 \& one of these ocular signs (BUT \<6sec or Schirmer test \< 5 mm/5min or corneal staining positive)
* Corneal thickness between 520-580 um.

Exclusion Criteria

* Patient with severe respiratory diseases (asthma, COPD and other bronchospactic diseases).
* Patient with cardiovascular diseases (Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock).
* Severe renal impairment (CrCl \<30 mL/min)
* Progressive diseases of the retina other than glaucoma
* Inflammation and/or infecctions active
* Ocular surface syndrome other than Ocular Surface disease
* Eyelid disorder
* Systemic adminsitration of Betablockers or carbonic anhydrase inhibitors
* Patient that requires another antigluacomatous eye drop other than fixed combination of Dorzolamide/Timolol
* Patients who use regularly lubricant eye drops
* Patient who use regularly contact lenses
* Patient with autoinmune diseases
* Patients who underwent kerato-refractive laser procedures, cornea or corneal surface surgery, including, but not limited to, LASIK and PRK, within 6 months prior to the baseline visit.
* Patients who have undergone a laser procedure or intraocular surgery or extraocular in either eye within 6 months prior to the baseline visit.
* Patients with severe central visual field loss in either eye based onclinical judgment of the investigator. For the Humphrey and Octopus perimeters, the severe loss The visual field is defined as a sensitivity less than or equal to 10 dB in at least two(2) of the four (4) visual field test points closest to the fixation point
* Patients with known hypersensitivity to any of the components of bothdrugs under study.
* Pregnant or lactating women.
* Women of childbearing age who are not using a contraceptive method.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No